(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Sutro Biopharma's earnings in 2026 is -$216,767,000.On average, 12 Wall Street analysts forecast STRO's earnings for 2026 to be -$162,396,417, with the lowest STRO earnings forecast at -$604,886,235, and the highest STRO earnings forecast at -$37,991,623. On average, 9 Wall Street analysts forecast STRO's earnings for 2027 to be -$118,546,635, with the lowest STRO earnings forecast at -$325,387,078, and the highest STRO earnings forecast at -$3,575,682.
In 2028, STRO is forecast to generate -$1,476,246 in earnings, with the lowest earnings forecast at -$1,418,354 and the highest earnings forecast at -$1,519,665.